Literature DB >> 33877451

Dystonia and leveraging oral pharmacotherapy.

Michelle Ann C Sy1, Hubert H Fernandez2.   

Abstract

Dystonia is a clinically diverse disorder, characterized by sustained or intermittent muscle contractions causing abnormal and often repetitive movements and/or postures. Accurate clinical diagnosis is tantamount to effective dystonia management. Current guidelines in the treatments of dystonia, including oral therapy, are prescribed to improve symptoms and to restore functional capacity. Identifying treatable causes from co-existing phenomenologies is relevant to provide the most optimal and disease-specific medications. In other forms of dystonia, genetic factors may affect outcome. Moreover, proper selection of patients, early initiation of medications and customized drug titration are keys to increasing the chances of success when using oral therapies for dystonia. Treatment of dystonia primarily involves agents that target dopamine and acetylcholine receptors. Other drugs used include benzodiazepines, baclofen, antiepileptics, some antipsychotics drugs and antihistamine, with different levels of evidence of effectiveness. Unfortunately, most of the widely used drugs have low levels of evidence and are primarily based on anecdotal experiences. Finally, other adjunctive therapeutic strategies are often necessary to complement oral therapy.

Entities:  

Keywords:  Dystonia; Genetic; Management; Pharmacotherapy; Treatment

Year:  2021        PMID: 33877451     DOI: 10.1007/s00702-021-02339-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  16 in total

1.  Improvement of cervico-trunco-brachial segmental dystonia with topiramate.

Authors:  Spiridon Papapetropoulos; Carlos Singer
Journal:  J Neurol       Date:  2005-11-22       Impact factor: 4.849

2.  Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.

Authors:  Charlotte L Mentzel; P Roberto Bakker; Jim van Os; Marjan Drukker; Glenn E Matroos; Hans W Hoek; Marina A J Tijssen; Peter N van Harten
Journal:  J Clin Psychiatry       Date:  2017-03       Impact factor: 4.384

3.  Amantadine hydrochloride treatment of tardive dyskinesia.

Authors:  B L Decker; J M Davis; D S Jonowsky; M K el-Yousef; H J Sekerke
Journal:  N Engl J Med       Date:  1971-10-07       Impact factor: 91.245

Review 4.  Treatment of dystonia.

Authors:  Joseph Jankovic
Journal:  Lancet Neurol       Date:  2006-10       Impact factor: 44.182

Review 5.  Dystonia: diagnosis and management.

Authors:  A Albanese; M Di Giovanni; S Lalli
Journal:  Eur J Neurol       Date:  2018-08-18       Impact factor: 6.089

6.  Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy.

Authors:  James Rice; Mary-Clare Waugh
Journal:  J Child Neurol       Date:  2009-02       Impact factor: 1.987

Review 7.  Dystonia: genetics and treatment update.

Authors:  Roongroj Bhidayasiri
Journal:  Neurologist       Date:  2006-03       Impact factor: 1.398

8.  Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl.

Authors:  R E Burke; S Fahn; C D Marsden
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

9.  Natural history of Oppenheim's dystonia (DYT1) in Israel.

Authors:  Marieta H Anca; Tcipora Falik Zaccai; Samih Badarna; Andres M Lozano; Anthony E Lang; Nir Giladi
Journal:  J Child Neurol       Date:  2003-05       Impact factor: 1.987

10.  The treatment of tardive dyskinesia with baclofen.

Authors:  W M Glazer; D C Moore; M B Bowers; B S Bunney; M Roffman
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  1 in total

Review 1.  The Patho-Neurophysiological Basis and Treatment of Focal Laryngeal Dystonia: A Narrative Review and Two Case Reports Applying TMS over the Laryngeal Motor Cortex.

Authors:  Maja Rogić Vidaković; Ivana Gunjača; Josipa Bukić; Vana Košta; Joško Šoda; Ivan Konstantinović; Braco Bošković; Irena Bilić; Nikolina Režić Mužinić
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.